Revolymer has agreed to divest its nicotine gum business to Alkalon A/S, retaining an equity stake and focusing on its core operations in functional polymers.
Information on the Target
On September 16, 2016, Revolymer (AIM: REVO) entered into an agreement to divest its nicotine gum business to Danish company Alkalon A/S. This strategic move follows an announcement made on June 20, 2016, and the finalization of the deal is contingent upon the fulfillment of customary conditions, including the transfer of key customer contracts and the Canadian product license to Alkalon.
Alkalon is well-positioned with EU regulatory approval for its products and a well-established customer base across Europe, complementing Revolymer's Canadian operations. The partnership opens avenues for both companies to enhance their market presence and explore new territories, leveraging economies of scale in manufacturing and marketing.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Canada
The nicotine gum market in Canada has shown resilience and growth potential driven by increasing awareness of smoking cessation products among health-conscious consumers. As smoking rates decline
Similar Deals
Erhvervsinvest → Fayrefield Ingredients Holding A/S
2024
Executive Capital → Quality Pellets
HALO Dream Inc. → Baby Merlin
2025
Alkalon A/S
invested in
Revolymer's nicotine gum business
in 2016
in a Other Private Equity deal
Disclosed details
Transaction Size: $1M
Net Income: $-1M
Equity Value: $1M
Multiples
P/E: -0.9x